##  [Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease](/us-en/news/media-releases/novartis-data-demonstrates-consistent-efficacy-and-tolerability-kisqali-combination-therapy-hrher2-advanced-breast-cancer-patients-difficult-treat-visceral-disease-0 "Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease") 

  Dec 08, 2018